Nucala

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Download Patient Information leaflet (PIL)
13-10-2022
Download Summary of Product characteristics (SPC)
13-10-2022
Download Public Assessment Report (PAR)
13-12-2021

Active ingredient:

Mepolizumab

Available from:

GlaxoSmithKline Trading Services

ATC code:

R03DX09

INN (International Name):

mepolizumab

Therapeutic group:

Лекарства за обструктивна заболявания на дихателните пътища,

Therapeutic area:

астма

Therapeutic indications:

Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Product summary:

Revision: 18

Authorization status:

упълномощен

Authorization date:

2015-12-01

Patient Information leaflet

                                92
Б. ЛИСТОВКА
93
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
NUCALA 100 MG ИНЖЕКЦИОНЕН РАЗТВОР В
ПРЕДВАРИТЕЛНО НАПЪЛНЕНА ПИСАЛКА
меполизумаб (mepolizumab)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ
КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или медицинска
сестра.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар,
фармацевт или медицинска
сестра. Това включва и всички възможни
нежелани реакции, неописани в тази
листовка. Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Nucala и за какво се
използва
2.
Какво трябва да знаете, преди да
използвате Nucala
3.
Как да използвате Nucala
4.
Възможни нежелани реакции
5.
Как да съхранявате Nucala
6.
Съдържание на опаковката и
допълнителна информация
7.
Инструкции за употреба стъпка по
стъпка
1.
КАКВО ПРЕДСТАВЛЯВА NUCALA И ЗА КАКВО СЕ
ИЗПОЛЗВА
Nucala съдържа активното вещество
МЕПОЛИЗУМАБ
, което е
_моноклонално антитяло_
. Това е вид
белтък, разработен да разпознава
специфични прицелни вещества в
орг
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Nucala 100 mg инжекционен разтвор в
предварително напълнена писалка
Nucala 100 mg инжекционен разтвор в
предварително напълнена спринцовка
Nucala 40 mg инжекционен разтвор в
предварително напълнена спринцовка
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Nucala 100 mg инжекционен разтвор в
предварително напълнена писалка
Всяка предварително напълнената
писалка с 1 ml съдържа 100 mg меполизумаб
(mepolizumab).
Nucala 100 mg инжекционен разтвор в
предварително напълнена спринцовка
Всяка предварително напълнена
спринцовка с 1 ml съдържа 100 mg
меполизумаб (mepolizumab).
Nucala 4
0 mg инжекционен разтвор в
предварително напълнена спринцовка
Всяка предварително напълнена
спринцовка с 0,4 ml съдържа 40 mg
меполизумаб (mepolizumab).
Меполизумаб е хуманизирано
моноклонално антитяло, получено чрез
рекомбинантна ДНК
технология в клетки от яйчник на
китайски хамстер.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Инжекционен разтвор (инжекция)
Бистър до опалесциращ, безцветен до
бледожълт или до бледокафяв разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Тежка еозинофилн
                                
                                Read the complete document

Similar products

Active ingredient Mepolizumab

Mepolizumab

ATC code R03DX09

R03DX09

Marketed by GlaxoSmithKline Trading Services

GlaxoSmithKline Trading Services

INN (International Name) mepolizumab

mepolizumab

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 13-10-2022
Summary of Product characteristics Summary of Product characteristics Spanish 13-10-2022
Public Assessment Report Public Assessment Report Spanish 13-12-2021
Patient Information leaflet Patient Information leaflet Czech 13-10-2022
Summary of Product characteristics Summary of Product characteristics Czech 13-10-2022
Public Assessment Report Public Assessment Report Czech 13-12-2021
Patient Information leaflet Patient Information leaflet Danish 13-10-2022
Summary of Product characteristics Summary of Product characteristics Danish 13-10-2022
Public Assessment Report Public Assessment Report Danish 13-12-2021
Patient Information leaflet Patient Information leaflet German 13-10-2022
Summary of Product characteristics Summary of Product characteristics German 13-10-2022
Public Assessment Report Public Assessment Report German 13-12-2021
Patient Information leaflet Patient Information leaflet Estonian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Estonian 13-10-2022
Public Assessment Report Public Assessment Report Estonian 13-12-2021
Patient Information leaflet Patient Information leaflet Greek 13-10-2022
Summary of Product characteristics Summary of Product characteristics Greek 13-10-2022
Public Assessment Report Public Assessment Report Greek 13-12-2021
Patient Information leaflet Patient Information leaflet English 13-10-2022
Summary of Product characteristics Summary of Product characteristics English 13-10-2022
Public Assessment Report Public Assessment Report English 13-12-2021
Patient Information leaflet Patient Information leaflet French 13-10-2022
Summary of Product characteristics Summary of Product characteristics French 13-10-2022
Public Assessment Report Public Assessment Report French 13-12-2021
Patient Information leaflet Patient Information leaflet Italian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Italian 13-10-2022
Public Assessment Report Public Assessment Report Italian 13-12-2021
Patient Information leaflet Patient Information leaflet Latvian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Latvian 13-10-2022
Public Assessment Report Public Assessment Report Latvian 13-12-2021
Patient Information leaflet Patient Information leaflet Lithuanian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-10-2022
Public Assessment Report Public Assessment Report Lithuanian 13-12-2021
Patient Information leaflet Patient Information leaflet Hungarian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 13-10-2022
Public Assessment Report Public Assessment Report Hungarian 13-12-2021
Patient Information leaflet Patient Information leaflet Maltese 13-10-2022
Summary of Product characteristics Summary of Product characteristics Maltese 13-10-2022
Public Assessment Report Public Assessment Report Maltese 13-12-2021
Patient Information leaflet Patient Information leaflet Dutch 13-10-2022
Summary of Product characteristics Summary of Product characteristics Dutch 13-10-2022
Public Assessment Report Public Assessment Report Dutch 13-12-2021
Patient Information leaflet Patient Information leaflet Polish 13-10-2022
Summary of Product characteristics Summary of Product characteristics Polish 13-10-2022
Public Assessment Report Public Assessment Report Polish 13-12-2021
Patient Information leaflet Patient Information leaflet Portuguese 13-10-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 13-10-2022
Public Assessment Report Public Assessment Report Portuguese 13-12-2021
Patient Information leaflet Patient Information leaflet Romanian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Romanian 13-10-2022
Public Assessment Report Public Assessment Report Romanian 13-12-2021
Patient Information leaflet Patient Information leaflet Slovak 13-10-2022
Summary of Product characteristics Summary of Product characteristics Slovak 13-10-2022
Public Assessment Report Public Assessment Report Slovak 13-12-2021
Patient Information leaflet Patient Information leaflet Slovenian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 13-10-2022
Public Assessment Report Public Assessment Report Slovenian 13-12-2021
Patient Information leaflet Patient Information leaflet Finnish 13-10-2022
Summary of Product characteristics Summary of Product characteristics Finnish 13-10-2022
Public Assessment Report Public Assessment Report Finnish 13-12-2021
Patient Information leaflet Patient Information leaflet Swedish 13-10-2022
Summary of Product characteristics Summary of Product characteristics Swedish 13-10-2022
Public Assessment Report Public Assessment Report Swedish 13-12-2021
Patient Information leaflet Patient Information leaflet Norwegian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 13-10-2022
Patient Information leaflet Patient Information leaflet Icelandic 13-10-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 13-10-2022
Patient Information leaflet Patient Information leaflet Croatian 13-10-2022
Summary of Product characteristics Summary of Product characteristics Croatian 13-10-2022
Public Assessment Report Public Assessment Report Croatian 13-12-2021

Search alerts related to this product

Alerts Nucala Mepolizumab

Nucala Mepolizumab

View documents history

Documents history Documents history

Nucala